Classement en actions
#2843
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops... CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Capitalisation boursière
$6.96B
Changement (1 jour)
0.80%
Changement (1 an)
210.23%
Échange CG Oncology Inc. (CGON)
EPS pour CG Oncology Inc. (CGON)
EPS au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de CG Oncology Inc., l’EPS actuel de la société (TTM) est de 0. À la fin de 2026, la société avait un EPS de 0 égal à celui de 2026, qui était de 0.
Historique de l'EPS de CG Oncology Inc. de 2026 à 2026
EPS à la fin de chaque année
| Année |
EPS |
Changez |
|
Pas assez de données pour les dates fournies. |
EPS pour des entreprises ou concurrents similaires
| Entreprise |
EPS |
Différence d’EPS |
Pays |
|
|
$17.32 |
-
|
US
|
|
|
$27.74 |
-
|
NL
|
|
|
$-7.98 |
-
|
US
|
|
|
$-5.29 |
-
|
AU
|
|
|
- |
-
|
CH
|